title: Morbidity and functional status of patients with pelvic neurogenic tumors after wide excision.
abstract: BACKGROUND
  We previously reported that over the last 10 years our practice has evolved in the treatment of neurogenic tumors of the pelvis to include a multispecialty team of surgeons, a factor that might decrease morbidity and improve recurrence, survival, and function.
  
  
  OBJECTIVE
  Therefore, we (1) assessed the morbidity associated with surgical excision in patients with neurogenic tumors of the pelvis; (2) determined the function of these patients; and (3) determined the rates of local recurrence, metastasis, and overall survival with this new approach.
  
  
  METHODS
  We reviewed the records of all 38 patients who had surgery for a pelvic plexus tumor between 1994 and 2005. Twenty one were male. The mean age of all patients was 38 years and median follow up was 2.1 years. Twelve patients had a malignant tumor. We recorded demographic data, postoperative complications, tumor-specific recurrence, and determined survival.
  
  
  RESULTS
  Postoperative complications occurred in nine of the 38 patients (23%): hematoma (n = 3), wound infection or deep abscess (n = 3), and deep venous thrombosis (n = 3). Surgical complications occurred more frequently in patients with malignant disease. Patients with benign tumors had a mean MSTS score of 94%, while survivors of malignant disease had a mean of 57%. For malignant tumors, the 5-year rate of local recurrence was 40%, the estimated 5-year rate of metastasis was 67% and 5-year survival rate was 50%.
  
  
  CONCLUSIONS
  Using a team approach, surgical excision provided high functional scores for patients with benign disease with a low rate of complications. In patients with malignant tumors, intentional wide resection is associated with higher morbidity but yields acceptable functional scores.
authors.affiliation: Department of Orthopedic Surgery, Mayo Clinic, 200 First, SW, Rochester, MN 55905, USA.
authors.forename: Joseph
authors.initials: J
authors.lastname: Alderete
authors.forename: Eduardo N
authors.initials: EN
authors.lastname: Novais
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Dozois
authors.forename: Peter S
authors.initials: PS
authors.lastname: Rose
authors.forename: Franklin F
authors.initials: FF
authors.lastname: Sim
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000401:mortality / Q000473:pathology / Q000503:physiopathology / Q000601:surgery*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D008910:Minnesota; D009364:Neoplasm Recurrence, Local; D009380:Neoplasms, Nerve Tissue / Q000401:mortality / Q000503:physiopathology / Q000556:secondary / Q000601:surgery*; D019637:Orthopedic Procedures / Q000009:adverse effects; D010384:Pelvic Bones / Q000473:pathology / Q000503:physiopathology / Q000601:surgery*; D020127:Recovery of Function; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult